MHRA to receive £10m from HM Treasury to fast-track patient access to cutting-edge medical products
The funding over the next two years will support development of a thorough but shortened process to speed up the approval process for cutting-edge treatments developed in the UK with the greatest opportunity to meet the UK’s healthcare priorities, such as cancer vaccines and AI-based therapeutics for mental ill-health.
HM Treasury has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10 million to help bring innovative new medicines and medical technologies to UK patients more quickly.